

Medicare Coverage Policy ~ NCDs

Breast Biopsy (#CAG-00040N)

Appendix A: Articles Reviewed

Author/ Journal/ Year	Type of Study	Outcomes Studied	Patient Characteristics	Results	HCF Con
<p>Acheson M, Patton RG, Howlsey RL, et al.</p> <p><i>Archives of Surgery</i></p> <p>1997</p> <p>"Histologic correlation of image-guided core biopsy with excisional biopsy on nonpalpable breast lesions"</p>	Nonrandomized prospective study	Histologic diagnoses of image-guided large core needle biopsies (LCNB) and excision specimens	552 patients with nonpalpable mammographic detected abnormalities	<p>Benign findings in 389 LCNB specimens</p> <p>Abnormal in 163 specimens</p> <p>Of benign findings, one malignant diagnosis missed.</p> <p>173 patients underwent excision following LCNB, 10 benign, 163 abnormal. 102 LCNB lesions confirmed on excision. Of 54 showing DCIS, 10 showed DCIS plus invasion on excision.</p>	Fair stud large LCNB follo exci shov sens spec imag core
<p>Bernstein JR.</p> <p><i>Seminars in Surgical Oncology</i></p> <p>1996</p> <p>"Role of stereotactic breast biopsy"</p>	<p>Review article</p> <p>Commentary</p>	NA	NA	<p>"Most patients who are referred for surgical excisional biopsy for a nonpalpable breast could have SNCB of their lesions." Radial scar is a contraindication.</p>	Artic com som docu stud his p note supp choi BIRA lesio

				contraindication.	lesio
<p>Bloodstone M, Dangle P, et al</p> <p><i>Annals of Surgical Oncology</i></p> <p>1999</p> <p>"One hundred consecutive advanced breast biopsy instrumentation procedures: complications, costs, and outcome"</p>	<p>Prospective Registry</p> <p>Patients with benign findings by ABBI were followed radiographically; patients with malignant findings by ABBI were advised to undergo therapeutic surgery.</p>	<p>Mammographic findings, procedure time, anesthesia type, pathologic findings, follow-up monitoring and overall costs of procedure</p> <p>Follow-up mammography within 6 months</p>	<p>100 women</p> <p>avg. age 62 years</p> <p>range 34-87 years</p> <p>breasts compressed to > 30 mm</p> <p>all lesions nonpalpable</p>	<p>99 patients underwent ABBI technique (1 women converted to OSB due to technical problems)</p> <p>60% lesions solid nodular, 27% microcalcification</p> <p>incision length 2.7 cm</p> <p>procedure time 20 min</p> <p>5 patients had complications</p> <p>55 pts had followup mammography – one missed lesion</p> <p>avg charge \$3406</p>	<p>Seve</p> <p>of M</p> <p>with</p> <p>lesio</p> <p>Ther</p> <p>seve</p> <p>failu</p> <p>devi</p> <p>Only</p> <p>mon</p> <p>the</p> <p>follo</p> <p>man</p> <p>Auth</p> <p>ABB</p> <p>pote</p> <p>ther</p> <p>tech</p> <p>alth</p> <p>labe</p> <p>diag</p>
<p>Burbank F, Parker SH, Fogarty TJ</p> <p><i>The American Surgeon</i></p> <p>1996</p> <p>"Stereotactic breast biopsy: improved tissue harvesting with the Mammotome"</p>	<p>Clinical trial</p> <p>For mammographic detected lesions requiring biopsy breast composition type was scored by the 4 point BIRAD system (score 1 breast tissue almost entirely fat, score</p>	<p>Comparison of weight and quality of biopsy specimens obtained by Mammotome and Biopty.</p> <p>quality of biopsy specimen, 5 scores:</p> <p>1- very good, full size, little blood, obtained quickly</p>	<p>284 women who underwent 345 Mammotome procedures</p> <p>mean age 52.7 years, age range 30-84 years</p> <p>Avg lesion 9.2mm</p>	<p>Authors found that Mammotome biopsies had higher scores than Biopty for all four BIRAD categories of breast composition.</p> <p>Percent of Mammotome</p>	<p>The</p> <p>spec</p> <p>are</p> <p>3 no</p> <p>sele</p> <p>who</p> <p>Biot</p> <p>inad</p> <p>sam</p> <p>inclu</p> <p>subj</p> <p>of th</p> <p>cate</p>

the Mammotome"	<p>4 breast tissues extremely dense) Quality of Mammotome biopsy specimen was compared to quality of Biopty biopsy specimens by breast composition type.</p> <p>Weight comparisons relied on 3 patients who underwent Biopty then Mammotome. "These 3 patients were selected for breast composition to obtain tissue from a mammo-graphically fatty breast, an average breast, and a dense breast" pg. 740.</p>	<p>obtained quickly</p> <p>2-good, 3/4 to full size, little blood, obtained quickly</p> <p>3-average (approximately the same as usually obtained by automated true cut device)</p> <p>4-poor, small amount, lots of blood, obtained very slowly</p> <p>5-inadequate, no histological diagnosis possible</p>		<p>biopsies which received quality scores of:</p> <p>1 (very good)- 84.9%</p> <p>2 (good)- 13%</p> <p>3 (average)- 2.1%</p> <p>For 3 patients Biopty was performed and then Mammotome- Mammotome specimens weighed two times more than Biopty (34.3 mg vs. 17.2 mg, $p=0.0002$)</p> <p>3 Mammotome related complications- 1 site infection, 1 painful hematoma, 1 marked pain during procedure</p>	com
<p>Burbank F</p> <p><i>The American Surgeon</i></p> <p>1997</p> <p>"Stereotactic breast biopsy: comparison of 14-</p>	<p>Not clear if all measures were prospective or if some were retrospective.</p> <p>186 lesions biopsied with 14 gauge Mammotome</p>	<p>Compare specimens obtained by 11 gauge and 14 gauge Mammotome devices for average aggregate tissue weight, average number of specimens, weight per specimen, time to harvest</p>	<p>Women who underwent 14 gauge Mammotome: mean age 55 years.</p> <p>Women who underwent 11</p>	<p>Comparison of 11 gauge vs. 14 gauge for:</p> <p>weight of breast tissue obtained - 1730 mg vs 1067 mg ($p\leq 0.0001$),</p>	The

Mammotome probe performance and complication rates"	62 lesions biopsies with 11 gauge Mammotome	specimen, number of specimens obtained per minute, and milligrams of tissue obtained per minute.	<p>Mammotome: mean age 54 years. Statistically significant difference between groups only for BIRADS scoring for breast composition.</p> <p>Almost all of the lesions were nonpalpable and were detected by imaging study.</p>	<p>specimens - 18 vs 27 ($p \leq 0.0001$),</p> <p>weight per specimen- 96mg vs 40mg ($p \leq 0.0001$),</p> <p>average tissue harvesting time- 15.6 min vs 15.4 min (not significant $p \geq 0.8$),</p> <p>weight of tissue harvested per minute - 111 mg/min vs 69 mg/min ($p \leq 0.0001$).</p> <p>Complications:</p> <p>14 gauge - 1 painful hematoma, 1 pain at incision site, 1 marked pain during procedure;</p> <p>11 gauge- 1 nonpainful hematoma (no statistically significant difference in complication rate)</p>	gau gau this proc the devi perf clini acqu expe the than whe man with devi
Burbank F	Retrospective study	Concordance of diagnosis between	Results are from 101 patients mean	The authors found a	Auth stat

<p><i>Radiology</i></p> <p>1997</p> <p>"Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: improved accuracy with directional, vacuum-assisted biopsy"</p>	<p>Compared diagnoses for lesions diagnosed as ADH or DCIS by percutaneous biopsy which also had followup surgical biopsy.</p> <p>The type of percutaneous biopsy performed (Biopty or Mammotome) was based solely on when the procedure was performed; before or after the treatment center switched from Biopty to Mammotome.</p>	<p>breast biopsy and open surgical biopsy for 113 lesions which had been diagnosed as ADH or DCIS at percutaneous biopsy</p>	<p>age range 37-85 years who had 113 lesions diagnosed as ADH or DCIS by percutaneous biopsy and followed up with open surgical biopsy.</p> <p>These patients were drawn from 997 women w/ 1,135 lesions who were referred to the treatment center, 1,041 lesions underwent percutaneous biopsy (765 automated tru cut, 276 directional vacuum assisted), 288 lesions were followed up by open surgical biopsy, 113 of these 288 lesions had been initially diagnosed as ADH or DCIS.</p>	<p>based diagnosis of ADH or DCIS to be statistically significantly more accurate (as confirmed by open biopsy) than a Biopty diagnosis.</p> <p>ADH diagnoses by percutaneous biopsy:</p> <p>of 18 ADH diagnoses by Biopty 8 were DCIS and 10 ADH or lesion gone by surgery,</p> <p>of 8 ADH diagnoses by Mammotome 8 were ADH or lesion gone by surgery (significant difference in upgrades $p<0.03$).</p> <p>DCIS diagnoses by percutaneous biopsy:</p> <p>of 55 DCIS diagnoses by Biopty 9 were IDC and 46 were DCIS or lesion gone by surgery,</p> <p>Of 32 diagnoses of DCIS by Mammotome 32 were DCIS or lesion gone by</p>	<p>difference between Mammotome Biopsy for DCIS ADH mean upgrade surgical biopsy. However, studies from general population retrospective studies excluded lesions ADH diagnosis percutaneous biopsy which did not undergo surgical biopsy of Mammotome. Procedure yielded "lesion" diagnosis cannot be that lesions initially by studies that would be that The selection were that reference clinical under management</p>
---	---	--	---	---	---

				(significant difference p=0.02).	not whe the palp Pote of b has stak com man Man devi
<p>Burbank F</p> <p><i>Radiology</i></p> <p>1997</p> <p>"Mammographic findings after 14-gauge automated needle and 14-gauge directional, vacuum-assisted stereotactic breast biopsy"</p>	<p>Clinical trial</p> <p>861 stereotactic breast biopsies were performed</p> <p>592 by 14-gauge automated needle,</p> <p>269 by 14-gauge directional, vacuum-assisted probe.</p> <p>Based on benign results from these biopsies 557 lesions were recommended for first imaging follow-up after 6 months.</p>	<p>Study radiologists (blinded to type of biopsy woman underwent) scored first follow-up mammogram compared to pre-biopsy mammogram.</p> <p>Score 1 = larger or more calcifications</p> <p>Score 2 = no meaningful change</p> <p>Score 3 = small decrease in lesion size or number of microcalcification</p> <p>Score 4 = no residual lesion</p>	<p>Study population comprised of women who underwent stereotactic breast biopsy, and complied with the recommendation to have first imaging follow-up of the biopsied lesion.</p> <p>Number of lesions = 495</p> <p>Number of women = ?</p> <p>Mean age of women 55 yrs</p>	<p>percent of lesions biopsied by automated needle / vacuum assisted device receiving various scores for first follow-up mammogram of lesions</p> <p>Score = 0 / 0</p> <p>Score 2 = 40 / 30</p> <p>Score 3 = 44/ 23</p> <p>Score 4 = 15 / 48</p>	<p>The sugg imag biop less disfi than biop caus conf inter futu man This pote term imag biop oper biop</p> <p>How stud failu a se imag for s biop scor radi wea asse com</p>

					of b has stak whic man Man devi
<p>Burbank F, Forcier N</p> <p><i>Radiology</i></p> <p>1997</p> <p>"Tissue marking clip for stereotactic breast biopsy: initial placement accuracy, long-term stability, and usefulness as a guide for wire localization"</p>	<p>Nonrandomized clinical trial</p> <p>Control group - 22 patients with benign lesions used to calibrate the accuracy of the measurement system</p> <p>149 patients underwent biopsy by 11- or 14-gauge Mammotome device with placement of a MicroMark metallic marker</p>	<p>Accuracy of placement of marker clip - distance off target as measured on post-biopsy mammogram (measured for 43 markers deployed by straight-needle method and 106 deployed by through-probe method)</p> <p>stability of placement of marker clip at first follow-up mammogram (measured for 31 lesions)</p> <p>usefulness of marker clip to guide wire localization before therapeutic breast surgery</p>	<p>171 patients</p> <p>22 patients in control group mean age 46.8 yrs</p> <p>age range 38-85 yrs</p> <p>149 patients in study group mean age 53.5 yrs</p> <p>age range 32-86 yrs</p> <p>Of 36 lesions which underwent subsequent surgical therapy, the marker was used as the target for wire localization in 28 lesions</p>	<p>average distance off target:</p> <p>12.6 mm for both marker deployment methods</p> <p>7.7 mm for control</p> <p>at first imaging followup average distance off target was 8.7 mm ($p>0.4$ for comparison to control, suggesting little migration from site of placement over time)</p>	<p>Dist</p> <p>estim</p> <p>base</p> <p>mea</p> <p>man</p> <p>ima</p> <p>for i</p> <p>(the</p> <p>estim</p> <p>inhe</p> <p>vari</p> <p>com</p> <p>sup</p> <p>avai</p> <p>Limit</p> <p>infor</p> <p>pati</p> <p>char</p> <p>and</p> <p>Not</p> <p>only</p> <p>were</p> <p>radi</p> <p>well</p> <p>were</p> <p>cont</p> <p>Stud</p> <p>som</p> <p>that</p> <p>pote</p> <p>erro</p> <p>into</p> <p>mar</p> <p>prov</p> <p>usef</p> <p>of le</p> <p>whic</p> <p>perc</p>

					all r evid lesio Pote of b have stak whic man Man Micr devi
<p>Cady B, Steele GD, Morrow M, et al.</p> <p><i>Cancer Journal for Clinicians</i></p> <p>1998</p> <p>"Evaluation of common breast problems: guidance for primary care providers"</p>	Review article	NA	NA	<p>In stereotactic breast biopsy section, authors note: "Its indiscriminate application in all breast lesions detected by mammography is unjustified, and its use in obvious cancers to confirm diagnosis before surgical excision is probably not cost-effective."</p>	<p>Revi sugg</p> <ul style="list-style-type: none"> • an clus micr and susp • Lo but repe repe a pa wan OSB <p>Thes seen cons limit Uncl auth thes</p>
<p>Chilcote WA, Quinn CA.</p> <p>1997</p> <p><i>Cleveland Clinic Journal of Medicine</i></p>	Review article	NA	NA	<p>Particularly useful for microcalcification</p> <p>Contraindication:</p> <p>Pts who cannot lie prone; obese</p>	<p>A go this nonp lesio</p> <p>Sup BIRA cove</p>

Medicine				breasts which compress to less than 2 cm	
"Stereotactic breast biopsy: a less-invasive option"					
<p>Cross MJ, Evans WP, Peters GN, et al</p> <p><i>Annals of Surgical Oncology</i></p> <p>1995</p> <p>"Stereotactic breast biopsy as an alternative to open excisional biopsy"</p>	Prospective	Concordance between histologic diagnosis and mammographic characterization	<p>225 women underwent 250 stereotactic biopsies</p> <p>avg age 54 years</p> <p>range 2-89 years</p> <p>Nonpalpable mammographic lesions</p>	<p>78% of lesions characterized as low suspicion of malignancy</p> <p>22% high suspicion</p> <p>97% of low suspicion lesions benign</p> <p>78% of high suspicion lesions were malignant</p> <p>Approx cost for stereotactic biopsy was \$1200</p>	<p>"Stereotactic breast biopsy: a reliable alternative to open biopsy in the management of breast disease"</p> <p>"alteration of open biopsy diagnosis for nonpalpable lesions"</p> <p>Like other articles emphasizing technical diagnosis, there is a focus on nonpalpable lesions rather than palpable lesions</p> <p>Specimen indication for stereotactic biopsy for nonpalpable lesions. Recommendation against excisional biopsy of axillary lesions</p>

<p>Galliano DE, Rosemurgy AS</p> <p><i>American Journal of Surgery</i></p> <p>1997</p> <p>"Stereotactic excisional breast biopsies utilizing the advanced breast biopsy instrumentation system"</p>	<p>clinical trial</p> <p>23 women underwent breast biopsy with the ABBI</p> <p>23 women underwent needle localization and excisional breast biopsy</p>	<p>of the mammographic lesion as measured by radiography of the biopsy specimen.</p> <p>Patient acceptance of the biopsy technique.</p>	<p>nonpalpable mammographically detected breast lesions; either microcalcifications or noncystic nodular densities suspicious for cancer</p> <p>Mean age: 62 years for ABBI, 68 years for OSB</p>	<p>acceptance of the ABBI system was high"</p> <p>Radiography of the biopsy specimens showed complete removal of the mammographic abnormality for all biopsies.</p> <p>No complications were reported.</p>	<p>that may in pa lesio iden ster man lesio breas or in breas pati lie p proc</p> <p>The not infor wou com diag accu ABB auth gold OSB</p>
<p>Fajardo LL, DeAngleis GA.</p> <p><i>Surgical Oncology Clinics of North America</i></p> <p>1997</p> <p>"The role of stereotactic biopsy in abnormal mammograms"</p>	<p>Review article</p>	<p>NA</p>	<p>NA</p>	<p>"For most asymmetric opacities or microcalcification stereotactic guidance is preferred. US guidance better for superficial lesions, breasts that compresses to less than 2 cm."</p>	<p>Poin perc breas shou used add to th worl</p> <p>Go stat accu com surg 90%</p>
<p>Ferzli GS, Hurwitz JB</p> <p><i>Surgical</i></p>	<p>Retrospective</p>	<p>Accuracy of specimen targeting, success rate of lesion removed,</p>	<p>34 consecutive patients who presented with nonpalpable</p>	<p>Of 28 biopsies, 27 specimens removed successfully</p>	<p>Atte emp exci than</p>

<p><i>Endoscopy</i></p> <p>1997</p> <p>"Initial experience with breast biopsy utilizing the advanced breast biopsy instrumentation"</p>		<p>complication</p>	<p>on mammography</p> <p>6 patients excluded.</p> <p>Mean age 49 years</p>	<p>Pathology malignant in 3 cases</p>	<p>How poor detail of two</p> <p>No s anal</p> <p>Lists cont such 300 to lie 30 n breas lesio ches</p> <p>Doe defin that com rem</p>
<p>Fuhrman G, Cederrborn G, Bolton J, et al.</p> <p><i>Annals of Surgery</i></p> <p>1998</p> <p>"Image-guided core-needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities"</p>	<p>Prospective study</p>	<p>Histologic diagnosis</p> <p>All patients with nonpalpable lesions evaluated by image-guided needle biopsy from 1993 to 1997</p> <p>Positive cores evaluated by wire-localization excisional breast biopsy.</p> <p>Sensitivity and specificity compared.</p>	<p>1440 image-guided breast biopsies performed.</p>	<p>Of 1440 image guidance biopsies, 1106 were benign. Only one pt found to have a cancer on followup.</p> <p>For ADH, there was 100% sensitivity, 88% specificity. For CIS, 65% sensitivity, 97% specificity.</p>	<p>Well stud dem exce sens spec facil</p> <p>Of n com ADH requ exci to d exte path such circu imag an a proc</p>
<p>Fuhrman G,</p>	<p>Prospective</p>	<p>Histologic diagnosis</p>	<p>451 patients over</p>	<p>367 benign</p>	<p>Focu</p>

<p>Champagne J, et al.</p> <p><i>Journal of Louisiana State Medical Society</i></p> <p>"Stereotactic core needle breast biopsy is an accurate diagnostic technique to assess nonpalpable mammographic abnormalities"</p>		<p>All cases evaluated by surgery dept to confirm pathologic finding</p>	18 months	<p>cases</p> <p>84 malignant cases</p> <p>one benign stereotactic biopsy proved to be malignant at subsequent surgical biopsy; one malignant core biopsy could not be confirmed at subsequent surgical biopsy</p>	<p>lesion calc</p> <p>Emp tech diag</p> <p>Includ eval not surg</p> <p>Fair man follow</p> <p>Exce accu histo eval man abno</p>
<p>Gisvold JJ, Goellner JR, Grant CS, et al</p> <p><i>AJR</i></p> <p>1994</p> <p>"Breast biopsy: a comparative study of stereotactically guided core and excisional techniques"</p>	Retrospective	<p>Pathologic features of core and excisional specimens compared</p>	<p>Of 471 patients referred to a breast imaging center for preop wire localization procedure, 104 patients underwent SNCB,</p>	<p>Of 104 lesions with at least 5 specimens 56 were benign and 48 malignant.</p> <p>Concordance between core and excisional biopsy was 96% for benign lesions, 83% for malignant lesions. Of 56 lesions with fewer than 5 specimens, 37 benign, 19 malignant. Concordance 81% for benign, 79% for malignant.</p> <p>2 malignant</p>	<p>All le nonp</p> <p>Poss bias</p> <p>No r follow beni</p> <p>No c conc base of sp</p> <p>Stat biop unn exper lesio app mali Sug ster</p>

				lesions missed on core biopsy.	lesion
<p>Israel PZ, Fine RE.</p> <p><i>The American Surgeon</i></p> <p>1995</p> <p>"Stereotactic needle biopsy for occult breast lesions: a minimally invasive alternative"</p>	Retrospective	<p>Histologic diagnoses</p> <p>Analysis of detected malignancies</p> <p>Compares histology of core biopsies with histology of open biopsies</p> <p>Lesions biopsied were indeterminate: microcalcification, nodular densities, stellate lesions, asymmetric densities with architectural distortions</p> <p>All patients are from one surgical practice</p>	500 consecutive stereotactic core biopsies in 454 patients in a surgical practice	<p>365 lesions – benign and no surgery recommended. 135 lesions went to OSB. Core biopsy followed by OSB when cores showed either malignancy or cytologic atypia.</p> <p>Of the 135 lesions, 88 cancers</p> <p>8 ductal hyperplasia, 9 fibroadenomas</p> <p>30 other</p> <p>18 core showing atypia went to OSB.</p> <p>6 showed atypia but no carcinoma</p> <p>6 benign</p> <p>6 showed in situ CA</p> <p>Only 2 cases in the 135 open biopsies (1.5%) failed to show a cancer that was present in OSB.</p>	<p>Very accurate diagnosis. However, does the only non-invasive alternative? Also, about up to 10% of benign lesions need ideal negative prediction.</p> <p>Set OSB as standard judgment some to re-OSB with suspicious mammogram and histologic guidance little here patients have gone</p> <p>Statistical percentage of biopsies silicone implants</p>

				sensitivity 85.4% specificity	
<p>Jackman RJ, Burbank F, Parker SH et al</p> <p><i>Radiology</i></p> <p>1997</p> <p>"Atypical ductal hyperplasia diagnosed at stereotactic breast biopsy: improved reliability with 14-gauge, directional, vacuum-assisted biopsy"</p>	Retrospective	<p>Compare accuracy of ADH diagnosis by 14 gauge automated large core biopsy or 14 gauge Mammotome biopsy with results of follow-up surgical excisional biopsy.</p> <p>Underestimation of carcinoma - lesions diagnosed as ADH at percutaneous biopsy which were later diagnosed as DCIS or invasive breast cancer at open surgical biopsy.</p>	<p>Patients who underwent large core biopsy:</p> <p>mean age 57 years</p> <p>age range 33-85 years</p> <p>55 nonpalpable breast lesions.</p> <p>Women who underwent Mammotome procedure: mean age 58 years</p> <p>age range 38-92 years</p> <p>88 nonpalpable breast lesions.</p> <p>No statistically significant differences between groups noted.</p>	<p>Of 54 lesions diagnosed as ADH by LCB and followed up with surgical biopsy - 18 DCIS, 8 IDC (26 carcinomas, 48% underestimation)</p> <p>Of 74 lesions diagnosed as ADH by Mammotome and followed up with surgical biopsy 10 DCIS, 3 IDC (13 carcinomas, 18% underestimation)</p> <p>for difference of underestimation rate $p < 0.0004$.</p> <p>The authors conclude that carcinoma is sufficiently underestimated by both LCB and Mammotome to necessitate surgical biopsy follow-up for diagnoses of ADH by either percutaneous procedure.</p> <p>3 complications out of total 793</p>	<p>The emp retr design lesio as A Mam 98% lesio by L docu have surg Resu pati a dia ADH perc biop wha did n surg und surg a sit infor unav rese</p> <p>Stud othe perc biop have com rate</p> <p>Parti repo diffe accu arise Mam proc</p>

				<p>Mammotome procedures (not just those diagnosed as ADH) 2 hematomas 1 infection. 6 complications out of 3,765 LCB procedures, 3 hematomas, 3 infections.</p> <p>Complication rate 0.14% vs 0.16%, $p>0.99$.</p> <p>Carcinoma underestimation mammotomies vs LCBs taking 10 or fewer specimens 44% vs 50%; for >10 specimens 10% vs 43%</p>	<p>signi spec LCB (15. $p<0$</p> <p>The a fir in th whic Man devi</p>
<p>Liberman L, LaTrenta L, Dershaw D, et al.</p> <p><i>AJR</i></p> <p>1997</p> <p>"Impact of core biopsy on the surgical management of impalpable breast cancer"</p>	Retrospective review	Compared impalpable breast carcinomas revealed by core biopsy with those revealed by surgical biopsy, with respect to frequency of performing a single surgical procedure and finding tumors at the margins of the lumpectomy specimen.	<p>197 solitary impalpable breast carcinomas</p> <p>90 core biopsy</p> <p>107 OSB</p> <p>median age core:</p> <p>59 yrs (33-85)</p> <p>median age OSB:</p> <p>57 yrs (35-87)</p> <p>other characteristics similar between ...</p>	<p>Single surgical procedure performed in 84% of the patients who underwent core biopsy vs 29% of patients who underwent surgical biopsy.</p> <p>$P<0.00001$</p> <p>Tumor margins present in 8% of core biopsy vs 5% by OSB ($p=0.7$)</p>	<p>A sin proc perf ofte with unde biop diffe obta free</p> <p>This g da pote redu num surg proc requ pati imn</p>

			statistical analysis not provided		can Wea inclu retro revie crite pati unde type prior
<p>Kelley, WE, Bailey, R, Bertelsen C, et al</p> <p><i>The Breast Journal</i></p> <p>1998</p> <p>"Stereotactic automated surgical biopsy using the ABBI biopsy device: a multicenter study"</p>	<p>Retrospective study</p>	<p>Characteristics of mammogram findings, size of ABBI biopsy, xray confirmation, surgical pathology, correlation of pathologic and radiologic findings.</p> <p>Need for second diagnostic procedures, incidence of postop complications, adequacy of cosmetic results, and postop analgesia</p>	<p>654 nonpalpable breast lesions were biopsied at 8 institutions</p> <p>No data on actual number of patients and age range</p>	<p>In all but one case, pathology correlated with mammographic findings (0.15%)</p> <p>1.8% complication rate</p> <p>99.8% cosmetic satisfaction</p> <p>2.4% pain med use</p>	<p>This key about desig num pati</p> <p>Man outc mea subj cosm and valu stat sign the repo</p> <p>If da accu good and com surg</p>
<p>Kessler H, Smith RL.</p> <p><i>American Journal of Managed Care</i></p> <p>1998</p> <p>"Managed Care</p>	<p>Commentary</p> <p>Includes brief description of 2 cases</p>	<p>NA</p>	<p>Case A: woman underwent stereotactic core biopsy</p> <p>Case B: woman underwent ultrasound directed core biopsy</p>	<p>Authors gives opinion that vacuum-assisted biopsy is safe and efficacious, with concordance equivalent to that of excisional biopsy for mass</p>	<p>Nice adv disa brea tech</p> <p>Stat nee proc res</p>

Case for Large-Core biopsy procedures in the diagnosis of breast cancer"			biopsy	lesions. Authors suggest that ability to perform stereotactic biopsy may be limited by breast size and lesion proximity to the chest wall. Author summarizes frequent criticism or suggested benefits of image-guided biopsies as alternative to OSB.	sens spec equi of op biop - re abno type This opin Of n abou over cover are
<p>Liberman L, Fahs MC, Dershaw D, et al.</p> <p><i>Radiology</i></p> <p>1995</p> <p>"Impact of stereotaxic core breast biopsy on cost of diagnosis"</p>	Retrospective analysis	Frequency with which stereotaxic core biopsy obviated diagnostic surgical biopsy; estimated savings in cost of diagnosis	<p>182 nonpalpable lesions, suspicious on mammography in 182 patients</p> <p>stereotaxic biopsy offered as an alternative to OSB</p>	<p>Stereotaxic core biopsy replaced a surgical procedure in 140 of 182 patients. Mean adjusted direct savings was *893.</p> <p>Decreased cost of diagnosis was 55%.</p>	<p>No s anal repo Lists and crite ster offer alter pati impt Focu rath char disti pref app Ever impe anal app expe tech mea</p>

					addi hype still OSB
<p>Liberman L, Feng TL, Dershaw, et al.</p> <p><i>Radiology</i></p> <p>1998</p> <p>"US-guided core breast biopsy: use and cost-effectiveness"</p>	Retrospective	<p>Frequency with which ultrasonographically guided core biopsy obviated diagnostic surgical biopsy of nonpalpable breast masses</p> <p>Cost estimates</p>	<p>151 consecutive solitary, nonpalpable breast masses in 151 women</p> <p>age range 23-80 yrs</p> <p>(out of 179 nonpalpable breast masses)</p>	<p>US-guided core biopsy obviated a surgical procedure in 85% of cases</p> <p>128/151</p> <p>Mean-adjusted cost savings \$744/case.</p> <p>If stereotactic guidance instead of US used, cost savings \$519/case</p>	Stat anal prov
<p>Liberman L, LaTrenta L, Van Zee KJ, et al</p> <p><i>Radiology</i></p> <p>1997</p> <p>"Stereotactic core biopsy of calcifications highly suggestive of malignancy"</p>	Retrospective review	<p>Frequency with which stereotactic core biopsy obviated a surgical procedure</p> <p>Cost estimates</p>	<p>31 women</p> <p>age 34-86 years</p> <p>All BIRADS 5 [highly suggestive of malignancy]</p> <p>Women underwent 14-gauge stereotactic core biopsy with an automated gun.</p>	<p>Of 31 patients:</p> <p>Stereotactic core—</p> <p>19 carcinoma</p> <p>8 ADH</p> <p>4 benign</p> <p>surgical biopsies recommended for 12 patients.</p> <p>Of the 19 pts, 2 chose surgical biopsy</p> <p>13 of 31 patients were spared a surgical procedure</p>	<p>Inter as it BIRA Ever high seve still ster biop amo surg proc avoi</p> <p>No s anal and anal in d info as it use ster biop</p>

				procedure. Cost savings estimated \$100/patient.	BIR Doe vacu devi
<p>Liberman L, Smolkin JH, Dershaw DD, et al.</p> <p><i>Radiology</i></p> <p>1998</p> <p>"Calcification retrieval at stereotactic, 11-gauge, directional, vacuum-assisted breast biopsy"</p>	Retrospective study	<p>Frequency of calcification retrieval by 11-gauge Mammotome - defined as identification of calcification on radiographic imaging of biopsy specimen</p> <p>Histologic underestimation - defined as stereotactic diagnoses of ADH upgraded to carcinoma or DCIS upgraded to infiltrating carcinoma at open surgical biopsy</p>	<p>80 women</p> <p>median age 55 years</p> <p>age range 31-85 years</p> <p>112 lesions detected on mammography as calcifications without a mass.</p> <p>All lesions underwent biopsy by 11-gauge Mammotome device.</p>	<p>Removal of all calcifications - 51 lesions (46%)</p> <p>removal of some calcifications - 55 lesions (49%)</p> <p>removal of no calcifications 6 lesions (5%) [4 of these 6 procedures were aborted- 1 secondary to mechanical failure, 1 to patient bleeding, 1 to patient vasovagal reaction, and 1 to patient nausea]</p> <p>surgical biopsy diagnosed DCIS in 1 of 10 (10%) lesions labeled ADH at percutaneous biopsy</p> <p>Surgical biopsy diagnosed infiltrating carcinoma in 1 of 21 lesions (5%) labeled DCIS at percutaneous biopsy.</p> <p>Authors noted</p>	<p>Sug biop Mam devi succ sam calci that diag disp surg</p> <p>Rep hist unde excl perc biop whic wha reas follo surg</p> <p>Of n stat loca can whe 11-g the Mam prob</p> <p>Auth opin gau man sup eval calci 14-g</p>

				<p>that failure to retrieve calcifications was more likely in small lesions, amorphous lesions, or lesions necessitating that the probe be fired outside of the breast (superficial lesion or thin breast)</p> <p>The authors noted that retrieval of all rather than some calcifications did not yield a statistically significantly lower rate of histologic underestimations (0 vs. 2 occurrences, no p value given)</p>	auto core
<p>Lind DS, Minter R, Steinbach B, et al.</p> <p><i>Journal of Surgical Research</i></p> <p>1998</p> <p>"Stereotactic core biopsy reduces the reexcision rate and the cost of mammographic detected cancer"</p>	Retrospective	Method of diagnosis, time interval from detection to diagnosis and breast-conserving surgery, volume of breast tissue excised, margin status and reexcision rate, number of surgical procedures, and total charges/costs per patient.	<p>117 patients with mammographically detected breast cancer who underwent breast-conserving surgery at the Univ of Florida.</p> <p>Patients who underwent mastectomy were excluded.</p>	<p>Malignancy 69 patients NLB</p> <p>48 patients SCB</p> <p>Time to diagnosis:</p> <p>6.8 days NLB</p> <p>1.7 days SCB p<0.01</p> <p>time to surgery:</p>	<p>Com outc mea with sign</p> <p>Of p imp fact stud dem redu reex</p> <p>Pron may</p>

				16.9 days NLB 8.1 days SCB $p < 0.01$ Vol excised: 75.2 cm ² NLB 117.9 cm ² SCB $p < 0.01$ Pos margin rate: 55% NLB 6% SCB $p < 0.01$ Reexcision rate: 50% NLB 2% $p < 0.01$ Total costs/pt: \$4853 NLB \$3537 SCB NLB=needle-localized surgical biopsy SCB=stereotactic core biopsy	anxi No stan crite whic met whic lesio unlik sign sele Focu nonp lesio Econ uses poss unre
Meyer JE, Smith	Not specified if	Presence of	Scant information	Radiography of	Not

<p>DN, DiPiro PJ, et al</p> <p><i>Radiology</i></p> <p>1997</p> <p>"Stereotactic breast biopsy of clustered microcalcification with a directional, vacuum-assisted device"</p>	<p>prospective, likely retrospective</p> <p>For five years clinic performed biopsies by 14 gauge Biopty procedure then for following 8 months by 14 gauge Mammotome procedure</p>	<p>biopsy specimen by radiography of specimen removed by 14 gauge Biopty or 14 gauge mammotome</p>	<p>patient selection.</p> <p>Patients had calcification clusters detected by imaging study.</p> <p>130 clusters were biopsied by Biopty, 106 clusters were biopsied by Mammotome</p>	<p>showed calcifications in 106 of 106 Mammotome obtained biopsy specimens (100%) and 118 of 130 LCB obtained biopsy specimens (90.8%), statistically significant difference between Mammotome and LCB, p=0.0006</p>	<p>prov rega char Pati eith perc biop on h the they proc anal whe char both grou simi</p>
<p>Meyer JE, Smith DN, Lester SC et al.</p> <p><i>JAMA,</i></p> <p>1999</p> <p>"Large-core needle biopsy of nonpalpable breast lesions"</p>	<p>Case series</p> <p>1333 lesions biopsied with 14-gauge Large Core Needle Biopsy (LCNB) by automated gun</p> <p>372 with 14-gauge LCNB and Directional Vacuum Assisted (DVA) device (Mammotome)</p> <p>131 with 11-gauge LCNB and DVA device (Mammotome)</p> <p>surgical excision to follow up malignancies detected by biopsy</p>	<p>Safety and accuracy of LCNB</p> <p>Confirmation of LCNB diagnosis by surgical excision only in certain cases: 43 lesions which were strongly suspicious by imaging study but had benign histology on LCNB,</p> <p>13 other lesions for variety of other reasons</p>	<p>Mean age 50 yrs</p> <p>age range 20-85</p> <p>1643 female subjects with 1836 nonpalpable lesions detected by mammogram or ultrasound</p> <p>mean mass size 1.3 cm., range 2mm - 4cm</p> <p>mean size calcification clusters 9mm</p> <p>range 2mm - 5.2cm</p>	<p>Complications of LCNB: 1 episode of pneumothorax, 1 of cellulitis</p> <p>Of 1424 lesions initially diagnosed as nonmalignant by LCNB, 202 were recommended for repeat biopsy (LCNB) based on correlation with abnormal mammogram or ultrasound, and technical quality of initial LCNB, detecting 32 cancers.</p> <p>For the 56 benign LCNB results which prompted confirmation by surgical excision</p>	<p>(Not refer Man subs</p> <p>Ther be a high imag abno whic norm resu furl inve Auth spec qual susp is th the diag surg</p> <p>Auth is cl larg of ti rem</p>

				<p>diagnosis confirmed</p> <p>Upgrade of diagnosis from LCNB to surgical excision:</p> <p>14 gauge DVA - of 24 diagnoses of ADH from calcium clusters - 7 upgrades to DCIS, 2 upgrades to IDC</p> <p>11 gauge DVA - of 9 diagnoses of ADH, 1 upgrade to DCIS</p> <p>14 gauge automated gun - of 18 lesions diagnosed as ADH 7 upgraded to DCIS and 3 to IDC</p>	<p>an u ADH diag LCN</p> <p>Give desi not biop are by o exci diffi cert form did r canc latte wou dete How bett mos on t</p> <p>Doe conc over</p>
<p>Park ST, Galbo C, Ghosh BC</p> <p><i>World Journal of Surgery</i></p> <p>1997</p> <p>"Stereotactic breast biopsy as an alternative to excisional biopsy"</p>	<p>Clinical trial</p> <p>Pilot study- 26 patients with suspicious nonpalpable mammo-detected lesions underwent stereotactic LCNB followed by needle localization and surgical excisional biopsy.</p> <p>Main study – 169 14-gauge stereotactic biopsies were performed</p>	<p>Usefulness of stereotactic core biopsy to decrease the number of mammographically suspicious lesions which necessitate surgical biopsy.</p>	<p>165 patients</p> <p>Age range 33-79 years</p> <p>169 lesions</p> <p>101 calcifications</p> <p>56 masses</p> <p>1 mass and calcifications,</p> <p>6 asymmetric densities, and 5 architectural distortions</p>	<p>For 26 patients in pilot study- no case of breast cancer was missed.</p> <p>For main study- 41 surgical biopsies were recommended, 36 were performed</p> <p>Of 6 atypia diagnoses at stereotactic biopsy, 5 went on to surgical biopsy, 3 were</p>	<p>Ther valu the conc serie ster biop whic follo surg pres decr num surg perf beni only does mali</p>

	surgical biopsy was recommended to follow-up any abnormal pathology or inadequate sampling.		distortions	<p>DCIS, 1 LCIS, 1 atypia. No false positives diagnoses of cancer at percutaneous biopsy.</p> <p>The authors suggest that using stereotactic biopsy to preselect which patients need surgical biopsy makes it possible to perform surgical biopsies in a way which yields malignant diagnosis 55% of the time (compared to a rate of 13.3% which the authors estimate would occur without preselection).</p>	impe know false diag occu perc biop all w conf surg The an a ster diag is un shou follo surg
<p>Parker SH, Lovin JD, Jobe WE, et al.</p> <p><i>Radiology</i></p> <p>1991</p> <p>"Nonpalpable breast lesions: stereotactic automated large-core biopsies"</p>	<p>Clinical trial</p> <p>102 stereotactic large-gauge needle core breast biopsies were performed (14 gauge) and were all followed up with needle localization and open surgical biopsy, and histologic diagnosis was made by the same pathologist</p>	Concordance of diagnosis by percutaneous and surgical biopsies	102 nonpalpable mammographic detected breast lesions	<p>Agreement of biopsy and surgical diagnosis in 98 of 102 cases (96%), 22 of 23 carcinomas (96%)</p> <p>1 case of IDC was found at surgery but missed by Biopty (lesion was close to chest wall and authors hypothesize the</p>	<p>Stud allow infor rega accu core biop to s as a were by b</p> <p>Wea pati infor prov be u</p>

				<p>was not properly localized)</p> <p>2 cases of fibroadenoma was diagnosed by Biopty and diagnosed as normal by surgery</p> <p>1 radial scar was called FCC by Biopty</p>	<p>BIR</p> <p>clas</p> <p>Ove</p> <p>were</p> <p>Of n</p> <p>publ</p> <p>and</p> <p>has</p> <p>sinc</p>
<p>Seoudi H, Mortier J, Basile R, Curletti E</p> <p><i>Arch Surg</i></p> <p>1998</p> <p>"Stereotactic core needle biopsy of nonpalpable breast lesions: initial experience with a promising technique"</p>	<p>Retrospective review</p> <p>Most biopsies were performed by Mammotome,</p> <p>12 biopsies were performed with 14-gauge needle and biopsy gun</p>	<p>Concordance between stereotactic core needle biopsy (SCNB) pathology result and the prebiopsy mammogram and pathology results of subsequent surgical excisions, when performed</p>	<p>97 female subjects with 100 nonpalpable breast lesions detected by mammogram</p> <p>mean age 58 yrs age range 30-85</p> <p>Mammographic lesions graded by American College of Radiology Breast Imaging Reporting and Data System</p> <p>5 grade V</p> <p>91 grade IV</p> <p>4 grade III</p>	<p>No significant complications of SCNB</p> <p>Discordance between SCNB and open surgical excision in 2 cases: one grade V lesion lipoma by SCNB later diagnosed as IDC by surgical excision,</p> <p>one grade IV lesion premalignant by SCNB, fibrocystic change by surgical biopsy</p>	<p>For</p> <p>IV le</p> <p>by S</p> <p>surg</p> <p>perf</p> <p>trust</p> <p>man</p> <p>follo</p> <p>not</p> <p>that</p> <p>fail t</p> <p>mali</p> <p>whic</p> <p>biop</p> <p>have</p> <p>Have</p> <p>stud</p> <p>low</p> <p>rate</p>
<p>Tomaselli, MB</p> <p><i>Surgical Physicians Assistant</i></p> <p>1998</p>	<p>Review article</p> <p>Describes 3 main categories of breast biopsy methods: surgical, core needle, and mammotome</p>	NA	NA	<p>p31 compared to surgical biopsy "strong evidence exists that the less invasive percutaneous biopsy, in general. and</p>	<p>Inter</p> <p>disc</p> <p>histo</p> <p>deve</p> <p>vari</p> <p>biop</p> <p>and</p> <p>desc</p>

breast biopsy methods: surgical, core needle, and mammotome"	mammotome.			vacuum assisted biopsy in particular, are more accurate, comfortable, cost effective, and timesaving."	the proc How infor besi auth to s use inva alter surg
<p>Velanovich V, Lewis FR, Nathanson D et al.</p> <p><i>Annals of Surgery</i></p> <p>1999</p> <p>"Comparison of mammographically guided breast biopsy techniques"</p>	<p>Review of all patients who underwent mammographically guided biopsies at one treatment center over a 15 month period.</p> <p>245 biopsies by 14-gauge SCNB</p> <p>107 biopsies by 11-gauge Mammotome</p> <p>104 biopsies by ABBI</p> <p>520 open surgical biopsies</p>	Technical success, pathology, discordance between pathologic diagnosis and mammographic image, need for open surgical biopsy	Not much information about patient characteristics except that they underwent biopsies during the time period of the study	<p>Authors conclude that ABBI provides the most efficient method of breast biopsy.</p> <p>Technical success: 94.3% for SCNB, 96.4% for Mammotome, 92.5% for ABBI, 98.7% for OSB</p> <p>Higher cancer yield for OSB than for other procedures (p<0.01)</p> <p>The discordance/re-biopsy rate was lower for ABBI than for Mammotome or SNCB (p=0.009)</p> <p>For cancerous lesions the 63.6% positive margin rate for ABBI was slightly higher than the 50.9% rate for OSB (p=NS)</p>	<p>Patie ranc assi biop and sugg patie mon lesio have pref stea OSB does suffi infor rega char whic and unde type proc</p> <p>All t seen spec few resu</p> <p>It is to d dete sens proc Iden</p>

				ABBI sensitivity was higher than Mammotome or SCNB (no p value given)	not not follo
<p>Zannis VJ, Aliano KM</p> <p><i>Am J Surg</i></p> <p>1998</p> <p>"The evolving practice pattern of the breast surgeon with disappearance of open biopsy for nonpalpable lesions"</p>	<p>Prospective clinical study</p> <p>One surgeon performed breast biopsies by 3 different techniques:</p> <p>stereotactic needle/wire localization with open biopsy (SNL/OBx),</p> <p>stereotactic needle core biopsy (SNCB),</p> <p>vacuum assisted biopsy (VAB)</p> <p>patients with abnormal histology by VAB or SCNB were advised to undergo SNL/OBx</p>	<p>study documented the number of biopsies performed by each technique</p> <p>SNCB employed a 14-gauge Tru-Cut needle and Biopty Gun</p> <p>VAB employed a Mammotome device with a 14 or 11-gauge probe</p>	<p>372 female subjects with</p> <p>424 mammography detected breast lesions</p> <p>average age 57 yrs</p>	<p>Over the entire study period total number of lesions biopsied by each method/number of initial abnormal histology results</p> <p>SNL/OBx - 190/ 81</p> <p>SNCB - 157/ 24</p> <p>VAB- 77/ 21</p> <p>follow-up lumpectomy for 43 of the 45 abnormal results of SNCB and VAB: histological upgrading for 4 SNCB and 0 VAB.</p> <p>Use of VAB increased over the study period while use of SNL/OBx and SNCB decreased.</p> <p>In the final 3 months of the study the surgeon used only VAB</p> <p>Complications</p>	<p>Artic char prac for c over</p> <p>Wou inter com accu to S</p> <p>Limiti infor rega sens (onl false resu dete repe man after</p> <p>Low rate</p> <p>No s anal diffe com rate proc</p> <p>Like stud subn focu nonp lesio</p>

				with SNL/OBx 12 occurrences of Cellulitis, 4 of abscess formation	
--	--	--	--	---	--

Breast Biopsy